JIE MA
Senior Principal Scientist at Adverum Biotechnologies- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
-
English Native or bilingual proficiency
-
Chinese Native or bilingual proficiency
Topline Score
Bio
Credentials
-
Post-doctoral research fellowship at SERI/MEEI/HMS
Harvard Medical School, Mass Eye and Ear, Schepens Eye Research InstituteMar, 2011- Nov, 2024
Experience
-
Adverum Biotechnologies
-
United States
-
Biotechnology Research
-
1 - 100 Employee
-
Senior Principal Scientist
-
Jan 2023 - Present
-
-
-
Adverum Biotechnologies, Inc
-
Redwood City, California, United States
-
Principal Scientist
-
May 2021 - Mar 2023
– Oversee the design and data-review of pre-clinical studies – Pilot studies testing safety and efficacy of vectors using rodents in house – Regulatory of the cooperations with CROs – Apply gene therapies to treat retinal diseases – Assay development for pre-clinical projects – Quality control – Oversee the design and data-review of pre-clinical studies – Pilot studies testing safety and efficacy of vectors using rodents in house – Regulatory of the cooperations with CROs – Apply gene therapies to treat retinal diseases – Assay development for pre-clinical projects – Quality control
-
-
-
Biogen
-
United States
-
Biotechnology Research
-
700 & Above Employee
-
Scientist II
-
Jan 2019 - May 2021
– Lead the projects of neuro-protection and neuro-regeneration related ophthalmological diseases using gene therapies (viral and non-viral deliveries) and other modalities – Oversee the assay developments to evaluate the efficacy of neuro-protection and neuro-regeneration – In charge of model generation of ocular diseases: ocular hypertension glaucoma model and optic nerve crush, TNF-a induced RGC death model – Neuroprotection by modifying inflammasome pathways – Lead the POC studies using SM, viral and non-viral treatments in ocular diseases – IACUC committee Show less
-
-
-
-
Senior Scientist
-
Jul 2016 - Jan 2019
Playing a key role in the Retinal Progenitor Program. Working on stem cell (iPS cells and ES cells) culture/maintain and stem cell differentiation for cell therapy. I was in charge of in vivo studies using cell therapies to treat rodent models with inherited ocular diseases including retinal photoreceptor degeneration, retinitis pigmentosa, and generating ocular diseases models including optic nerve degeneration and ocular hypertension. Playing a key role in the Retinal Progenitor Program. Working on stem cell (iPS cells and ES cells) culture/maintain and stem cell differentiation for cell therapy. I was in charge of in vivo studies using cell therapies to treat rodent models with inherited ocular diseases including retinal photoreceptor degeneration, retinitis pigmentosa, and generating ocular diseases models including optic nerve degeneration and ocular hypertension.
-
-
-
Harvard Medical School
-
United States
-
Higher Education
-
700 & Above Employee
-
Instructor, Junior Faculty
-
Feb 2014 - Jul 2016
Generated ocular disease rodent models including age-related macular degeneration (AMD), ocular hypertension (glaucoma) and optic nerve degeneration; Intravitreally administrated gene therapy, cell therapy and specific inhibitor/receptor to treat AMD or glaucomatous mice; Estimated solid method to quantify retinal ganglion cells (RGCs) using specific markers; Investigated inflammation enhancing RGC death in gluacomatous mice. As a key investigator, I was in charge of supervising students and technicians in the lab and managing the projects. Show less
-
-
-
Massachusetts Eye and Ear
-
United States
-
Hospitals and Health Care
-
700 & Above Employee
-
Investigator, Junior Faculty
-
Feb 2014 - Jul 2016
Generated ocular disease rodent models including age-related macular degeneration (AMD), ocular hypertension (glaucoma) and optic nerve degeneration; Intravitreally administrated gene therapy, cell therapy and specific inhibitor/receptor to treat AMD or glaucomatous mice; Estimated solid method to quantify retinal ganglion cells (RGCs) using specific markers; Investigated inflammation enhancing RGC death in gluacomatous mice. As a key investigator, I was in charge of supervising students and technicians in the lab and managing the projects. Show less
-
-
-
Schepens Eye Research Institute / Harvard Medical School
-
20 Staniford St, Boston
-
Postdoctoral Fellow
-
Mar 2011 - Jan 2014
Generated ocular disease rodent models including age-related macular degeneration (AMD), ocular hypertension (glaucoma) and optic nerve degeneration; Intravitreally administrated gene therapy, cell therapy and specific inhibitor/receptor to treat AMD or glaucomatous mice; Estimated solid method to quantify retinal ganglion cells (RGCs) using specific markers; Investigated inflammation enhancing RGC death in gluacomatous mice. As a key investigator, I was in charge of supervising students and technicians in the lab and managing the projects. Show less
-
-
-
Georgetown University
-
United States
-
Higher Education
-
700 & Above Employee
-
Research Associate
-
Aug 2009 - Mar 2011
Studies of neurophysiology, neuro-morphology and pharmacology.
-
-
Postdoctoral Fellow
-
Jul 2008 - Jul 2009
Studies of neurophysiology and animal behavior
-
-
-
UCLA
-
United States
-
Higher Education
-
700 & Above Employee
-
Postdoctoral Fellow
-
Mar 2004 - Feb 2007
Neurophysiology, pharmacology, animal behavior Neurophysiology, pharmacology, animal behavior
-
-
Education
-
University of Chinese Academy of Sciences
Doctor of Philosophy - PhD, Ecology and Behavior -
Beijing Normal University
Master’s Degree, Animal Ecology and Physiology -
Beijing Normal University
Bachelor’s Degree, Biology